Weiss Multi Strategy Advisers LLC Viridian Therapeutics, Inc.\De Transaction History

Weiss Multi Strategy Advisers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $74,181 - $150,097	-6,671 Reduced 5.07%	125,000 $2.72 Million
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $372,632 - $607,126	-24,580 Reduced 15.73%	131,671 $2.02 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $2.08 Million - $2.74 Million	92,283 Added 144.26%	156,251 $3.72 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $99,358 - $149,196	3,968 Added 6.61%	63,968 $1.63 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $187,800 - $297,400	-10,000 Reduced 14.29%	60,000 $1.75 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $481,082 - $1.15 Million	44,961 Added 179.56%	70,000 $1.44 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $239,122 - $475,741	25,039 New	25,039 $290,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.